CUAMC
VRNA

China Universal Asset Management Company’s Verona Pharma VRNA Stock Holding History

China Universal Asset Management Company’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,838
Closed -$1.58M – 534
2025
Q3 		$1.58M Sell
14,838
-8,123
-35% -$848K 0.13% 133
2025
Q2 		$2.17M Sell
22,961
-6
-0% -$444 0.2% 99
2025
Q1 		$1.46M Buy
22,967
+119
+0.5% +$7.12K 0.14% 140
2024
Q4 		$1.06M Buy
22,848
+1,807
+9% +$67.8K 0.1% 156
2024
Q3 		$605K Buy
21,041
+5,691
+37% +$140K 0.07% 196
2024
Q2 		$222K Sell
15,350
-4,850
-24% -$70.8K 0.03% 226
2024
Q1 		$325K Buy
20,200
+5,322
+36% +$92K 0.04% 231
2023
Q4 		$296K Sell
14,878
-40,806
-73% -$603K 0.06% 177
2023
Q3 		$908K Buy
55,684
+34,811
+167% +$670K 0.26% 85
2023
Q2 		$441K Buy
20,873
+20,011
+2,321% +$427K 0.14% 111
2023
Q1 		$17.3K Buy
862
+245
+40% +$5.29K 0.01% 233
2022
Q4 		$16.1K Buy
+617
New +$8.22K 0.01% 188

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

China Universal Asset Management Company's VRNA Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 14,838 shares — an estimated $1.58M sold.

China Universal Asset Management Company first reported a position in VRNA in Q4 2022 and held it in 12 quarters. The position peaked at $2.17M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • China Universal Asset Management Company reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 14,838 Verona Pharma shares in Q4 2025, an estimated $1.58M.
  • China Universal Asset Management Company first reported a position in Verona Pharma in Q4 2022 and held it in 12 quarters.
  • China Universal Asset Management Company's Verona Pharma position peaked at $2.17M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.